TScan Therapeutics (NASDAQ:TCRX) Rating Lowered to Equal Weight at Morgan Stanley

TScan Therapeutics (NASDAQ:TCRX) was downgraded by equities researchers at Morgan Stanley from an “overweight” rating to an “equal weight” rating in a report released on Friday, Marketbeat.com reports.

TCRX has been the topic of a number of other research reports. HC Wainwright dropped their target price on TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Thursday. BTIG Research cut shares of TScan Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 4th. Needham & Company LLC cut their price objective on shares of TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a report on Wednesday, October 8th. Finally, Wedbush reiterated an “outperform” rating and set a $7.00 price target on shares of TScan Therapeutics in a research note on Tuesday, August 12th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $6.60.

TScan Therapeutics Price Performance

Shares of NASDAQ:TCRX opened at $1.10 on Friday. TScan Therapeutics has a one year low of $1.02 and a one year high of $4.94. The stock has a market capitalization of $62.43 million, a price-to-earnings ratio of -0.98 and a beta of 1.00. The company has a 50-day simple moving average of $1.84 and a 200-day simple moving average of $1.70. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.06 and a current ratio of 6.44.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.07. The firm had revenue of $2.51 million for the quarter, compared to analyst estimates of $1.98 million. TScan Therapeutics had a negative return on equity of 73.33% and a negative net margin of 1,692.96%. On average, analysts predict that TScan Therapeutics will post -1.12 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BVF Inc. IL lifted its position in shares of TScan Therapeutics by 63.6% during the 1st quarter. BVF Inc. IL now owns 4,889,474 shares of the company’s stock valued at $6,747,000 after acquiring an additional 1,900,000 shares during the period. Aberdeen Group plc increased its stake in TScan Therapeutics by 52.0% in the 3rd quarter. Aberdeen Group plc now owns 1,354,820 shares of the company’s stock valued at $2,466,000 after purchasing an additional 463,372 shares in the last quarter. Checkpoint Capital L.P. raised its holdings in TScan Therapeutics by 14.9% during the first quarter. Checkpoint Capital L.P. now owns 2,017,650 shares of the company’s stock worth $2,784,000 after purchasing an additional 261,663 shares during the last quarter. Jane Street Group LLC purchased a new stake in TScan Therapeutics during the second quarter worth $309,000. Finally, Vanguard Group Inc. boosted its position in TScan Therapeutics by 7.8% during the third quarter. Vanguard Group Inc. now owns 2,317,916 shares of the company’s stock worth $4,219,000 after purchasing an additional 168,540 shares in the last quarter. 82.83% of the stock is currently owned by institutional investors and hedge funds.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.